Mefexamide

Mefexamide

SCHEMBL126334

CCN(CC)CCNC(=O)COc1ccc(OC)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP3A4 P08684 1/20 0.97
ALDH1A1 P00352 4/20 0.61
PTPN1 P18031 1/20 0.58
MAPT P10636 3/20 0.52
MAPK1 P28482 1/20 0.52
KDM4E B2RXH2 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GAA P10253 2/20 0.52
POLB P06746 1/20 0.51
USP2 O75604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mefexamide SCHEMBL364170 0.99 CYP3A4 (1.00) CYP1A2CYP2D6CYP3A4ALDH1A1PTPN1
Mefexamide SCHEMBL1650022 0.97 CYP1A2 (0.95) CYP1A2CYP2D6CYP3A4ALDH1A1PTPN1
Clofexamide SCHEMBL1604514 0.87 CYP1A2 (0.78) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
Clofexamide SCHEMBL365077 0.86 CYP3A4 (0.78) CYP1A2CYP2D6CYP3A4ALDH1A1KDM4E
SCHEMBL7002893 0.84 CYP1A2 (0.73) CYP1A2CYP2D6CYP3A4ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL11539142 0.83 CYP3A4 (0.73) CYP1A2CYP2D6CYP3A4KDM4ESMN1; SMN2
SCHEMBL10379993 0.79 LMNA (0.68) CYP1A2CYP2D6CYP3A4ALDH1A1MAPK1
Formic Acid SCHEMBL6325576 0.78 CYP1A2 (0.64) CYP1A2CYP2D6CYP3A4ALDH1A1PTPN1
SCHEMBL7701481 0.78 CYP1A2 (0.63) CYP1A2CYP2D6CYP3A4ALDH1A1PTPN1
SCHEMBL7266793 0.77 CYP1A2 (0.62) CYP1A2CYP2D6CYP3A4ALDH1A1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3635130-A1 PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY Indiana University Research and Technology Corporation (US) 2020-04-15 EP claimed
WO-2018209341-A1 PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-11-15 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
US-8026285-B2 Control release of biologically active compounds from multi-armed oligomers BEZWADA BIOMEDICAL, LLC (US) 2011-09-27 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS BEZWADA BIOMEDICAL, LLC (US) 2009-03-19 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
US-6174890-B1 A SYNERGISTIC BIOLOGICAL, NEUROMETABOLIC AND CELLTROPHIC COMPOSITION COMPRISING ANTIOXIDATIVE AND -CATABOLIC STRESS (METHIONINE),-ANABOLIC DRUGS, VASODILATIVE AND NORMO-LIPIDEMIC DRUGS (NICOTINIC ACID), ENERGOACTIVE AND ANTITOXIC RIGA DAN (RO) 2001-01-16 US claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-6010715-A SUSTAINED DRUG RELEASE; MONOLITHIC CARRIER BERTEK, INC. (US) 2000-01-04 US claimed
EP-0804239-B1 ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF RIGA DAN (RO) 1999-09-15 EP claimed
EP-0563507-B1 Transdermal patch incorporating a polymer film incorporated with an active agent BERTEK INC (US) 1998-05-27 EP claimed
EP-0804239-A1 ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF Riga, Dan (RO) 1997-11-05 EP claimed
US-5679373-A MELT-BLENDING THERMOPLASTIC MATRIX; IMPERMEABLE BACKING; LAMINATION WITHOUT ADHESIVE; CONTROLLED RELEASE BERTEK, INC. (US) 1997-10-21 US claimed
US-5662926-A SOLVENT FREE BERTEK, INC. (US) 1997-09-02 US claimed
WO-1995033486-A1 ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF RIGA DAN (RO) 1995-12-14 WO claimed
EP-0563507-A1 Transdermal patch incorporating a polymer film incorporated with an active agent MLI ACQUISITION CORP. II (US) 1993-10-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS MME, CTSA, ALG1 CYP1A2 3562/4885CYP2D6 3091/4885CYP3A4 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.